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Summary As part of a larger study designed to investigate the interaction of factors such as cirrhosis and
hepatitis B virus infection as aetiological agents in the development of hepatocellular carcinoma, we inves-
tigated the status of hepatic HBV-DNA sequences in 156 cirrhotic patients. Forty-one were HBsAg
seropositive and 18 (44%) of these had HBV-DNA sequences detectable in their livers. There are also 26
subjects who showed markers of a previous HBV infection (anti-HBs/anti-HBc), only one (4%) of whom had
demonstrable hepatic HBV-DNA sequences. No sequences were found in any of the remaining 89 patients
who were seronegative for all markers. Thus, liver HBV-DNA was only detected in the presence of a serum
marker, usually HBsAg.
Epidemiological studies based on serum markers have impli-
cated the hepatitis B virus (HBV) in the aetiology of
hepatocellular carcinoma (HCC) (Szmuness et al., 1978;
Beasley, 1982) and in some instances integrated HBV-DNA
was detected in the genome of tumour cells (Popper et al.,
1987; Brechot et al., 1981, 1983). Following reports that
hepatic HBV-DNA could be detected in non-tumorous tissue
and in chronic HBV carriers (Shafritz et al., 1981; Brechot et
al., 1982), it was suggested that detection of integrated HBV-
DNA might define patients at risk of developing HCC.
We are currently undertaking a large prospective study of
cirrhotic patients aimed at delineating risk factors such as the
presence of serum markers of HBV infection, which may be
associated with an increased risk of malignant change. In
view of reports that hepatic HBV-DNA could occasionally
be detected even in the absence of conventional serum
markers (Vergani et al., 1982; Brechot et al., 1985), it became
important to assess the frequency of hepatic HBV-DNA in
relation to HBV serum markers. We now present our
findings on hepatic HBV-DNA in a series of 156 biopsies
from cirrhotic patients with various forms of long established
liver disease including HCC.
Material and methods
Liver biopsies were performed on 156 patients, the majority
of whom were of Northern European extraction (102,
65.4%), while the remainder were from Southern Europe and
other Mediterranean regions (39, 25%), Arabian and Asian
subcontinent (10, 6.4%), the Far East (3, 1.9%) and Africa
(2, 1.3%). One hundred and two were male and 54 female.
All patients had histologically proven cirrhosis. Of the 138
subjects without HCC, 66 had chronic active hepatitis
(CAH), of which 46 had HBV serum markers, 11 were of the
autoimmune type (SMA/ANF > 1:80) and nine were
'idiopathic', probably due to non-A non-B infection. Seven
of the latter were from the Middle East, and two were
hospitalised for acute NANB hepatitis; in both cases a diag-
nosis of cirrhosis was made 1 year later. The remainder
comprised patients with alcoholic (ALC) 26, primary biliary
cirrhosis (PBC) 33, cryptogenic five, secondary biliary cirr-
hosis three, Wilson's disease two and one each with alpha-l-
antitrypsin disease, Budd-Chiari and haemochromatosis
(Table I).
Also investigated were 18 subjects with HCC, eight of
whom had previously been diagnosed as having cirrhosis
without tumour, while the other 10 presented with tumour
on cirrhosis. One HCC patient had tumour as well as sur-
rounding tissue analysed.
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Table I Serum markers of HBV infection in relation to liver
histology
Aetiology HBsAg + ve HBsAg -ve
of Anti-HBsl
cirrhosis No. HBeAg HBeAb anti-HBc None
CAH 66 13 19 14 20
Alcoholic 26 - 1 3 22
PBC 33 - - - 33
Cryptogenic 5 - - 1 4
Othera 8 - - 3 5
HCC 18 2 5 6 5
aSecondary biliary cirrhosis (3), Wilson's Disease (2), a-I
antitrypsin deficiency (1), Budd-Chiari syndrome (1) and
haemochromatosis (1).
Serological analysis
Serological markers of HBV infection: HBsAg, HBeAg, anti-
HBe, anti-HBs and anti-HBc were tested for by standard
radio-immunoassay techniques (Abbott Laboratories, UK).
All patients who were HBsAg seropositive but showed no
hepatic HBV-DNA were tested for delta antigen (Abbott
Laboratories UK).
Liver biopsy analysis
Liver biopsies were performed using Menghini or Trucut
needles. Part of the biopsy was placed in 10% formol-saline
for routine histological examination, and the other half was
snap frozen in liquid nitrogen and stored at - 70C. Liver
HBV-DNA was assessed without knowledge of either the
final histological diagnosis or the routine HBV serology.
DNA analysis
DNA was prepared from homogenized liver using a lysis
buffer (NaCl, Tris, EDTA, 10 mM, pH 7.8), 0.5% SDS and
digested with 1% pronase at 37C for 16-20 h. It was further
purified by three extractions with phenol, phenol: chloro-
form:isoamyl alcohol (25:24:1) and chloroform: isoamyl
alcohol (24:1). The DNA was then precipitated with 2vols
chilled 100% ETOH and 0.3 M sodium acetate solution
(pH 5.2) for 4 h at - 70°C. DNA was redissolved in a 10 mM
Tris, 1 mM EDTA buffer (pH 7.5) and treated with DNAse
free RNAse Al, added to a final concentration of
100 jig ml-' for 90 minutes at room temperature (Maniatis et
al., 1982). The extraction procedure was repeated and DNA
purity checked by OD determinations at 260/280 nM. Sam-
ples were stored at - 70°C.
Ten micrograms of DNA were digested with Eco RI and
Hind III for 16 h at 37°C. Digested samples were run in
parallel with 10 Lg of undigested DNA on slab electro-
phoresis gels containing 0.85% agarose at 2Vcm' over 16
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hours. Gels were stained with 0.5 fig ml-' ethidium bromide
and photographed to confirm the DNA yield. DNA was
partially hydrolysed by acid depurination to facilitate large
fragment transfer. DNA was transferred to 'Genescreen Plus'
(NEN) nylon-bonded membrane by Southern blotting for
24h (Southern, 1975) and stained with ethidium bromide to
confirm transfer.
Blots were prehybridised in buffer containing 1 M NaCl,
1% SDS, and 20% dextran sulphate diluted 1:1 with
deionised formamide for 20 h at 42C (Wahl et al., 1979). At
this point cloned HBV-DNA labelled with 32P-deoxycytidine
triphosphate by nick translation (Rigby et al., 1977) was
added to the prehybridisation mixture together with sheared
denatured salmon sperm DNA to a final concentration of
100 yg ml -. The specific activity of labelled probe was in the
order of 5 x 108 c.p.m. ptg' DNA and the sensitivity of the
assay, in our hands, was a level of 1 pg. The plasmid pHBV
130.4, which contained the probe (kindly provided by Profes-
sor K. Murray, University of Edinburgh), was digested by
Xho I. The insert was then separated by electrophoresis and
purified by electroelution.
Following the manufacturer's instructions for stringent
washing, blots were autoradiographed in Kodak cassettes
fitted with fine intensifying screens using Kodak X-OMAT
AR film for up to 7 days at - 70'C (Lasky & Mills, 1977).
After autoradiography the probe was stripped with 0.4 N
NaOH at 42°C for 30 minutes and washed in a 0.1SSC:0.1%
SDS:0.2 M Tris buffer (pH 7.5) before reprobing with plas-
mid vector DNA.
After digestion with restriction enzymes, episomal DNA
was considered present on autoradiographs when bands were
detected at 3.2 kilobase pairs (kbp), replicating DNA when
sequences were found at less than 3.2 kbp, and integrated
DNA when bands were found at higher molecular weights
(>3.2 kbp). Figure 1 shows typical examples of replicating,
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Figure I Sequences in three patients (C, D, F) with hepatocel-
lular carcinoma, and one patient (E) with long standing crypto-
genic cirrhosis. Lanes Al and A2, molecular weight markers; lane
B, HBV-DNA standard preparation; all lane Is, ECO RI digest
of 10 pg DNA; all lane 2s, HIND III digest of 10 Lg DNA; all
lane 3s, undigested DNA; CI-3, high molecular weight HBV-
DNA only; Dl-3 and F I, episomal and replicating sequences;
F2 and 3, episomal, replicating and integrated sequences.
integrated and combined forms as detected in three HCC
patients. Each gel was run with both "5S-radiolabelled Hind
III fragments of bacteriophage DNA as well as cloned HBV-
DNA. These were run as molecular weight markers and a
positive 3.2 kbp control, respectively.
Results
Of the 34 patients with uncomplicated cirrhosis who were
HBsAg positive, 13 (38%) had HBeAg seropositive CAH
(Table I). Replicating and/or episomal genomic HBV DNA
was found in six of them and both free and integrated forms
in one other. The remaining 21 patients had anti-HBe, 20
with CAH and one with alcoholic cirrhosis, five of them
showing replicating non-integrated HBV-DNA. In none of
the other 104 HbsAg negative subjects, 20 of whom had
anti-HBs/anti-HBc, was HBV-DNA demonstrated (Table II).
Among the 18 HCC patients two were HBsAg/HBeAg
positive. One of them showed replicating sequences, the other
showed both episomal/replicating and integrated forms. Of
the five HBsAg/anti-HBe positives, three had both forms and
one had integrated forms only. There were six subjects with
markers of past infection. Five of these showed no sequences,
but one (patient C), who was seropositive for both anti-HBs
and anti-HBc, showed high molecular weight HBV-DNA at
approximately 8.0 kbp (Figure 1, patient C, lanes 1, 2, 3).
This was reprobed with 32P-radiolabelled plasmid and found
to be negative, indicating no contamination from vector
DNA. No HBV-DNA was detected among the remaining
five patients. One patient within this group had both tumour
and non-tumour tissue examined and in the presence of
serum HBsAg/anti-HBe, both integrated and replicating
forms were found in the tumour, but only replicating forms
in the non-tumour tissue.
Among those six patients in whom no HBV-DNA
sequences could be detected despite the presence of HBeAg,
there were two patients who were seropositive for infection,
two on antiviral therapy and two others who were
seronegative for DNA polymerase activity.
Discussion
As expected, we found a significantly higher prevalence of
hepatic HBV-DNA in the surface antigen positive group than
in the seronegative group. Indeed, among 115 subjects who
were HBsAg seronegative, only one, albeit with HCC,
showed HBV-DNA sequences in the liver. This contrasts
with earlier studies reported by Brechot et al. (1982, 1983,
1985) and Nalpas et al. (1985), who detected HBV-DNA
sequences, in the absence of conventional seropositivity, in
approximately 27% of patients with chronic liver disease and
93% of patients with HCC. Our results are in accord with
recent studies on HBsAg seronegative alcoholic liver disease
by Walter et al. (1988), who investigated 47 patients (17 of
whom had HCC), and Fong et al. (1988), who studied 47
biopsies (five from patients with HCC). Both studies failed to
detect HBV-DNA in these liver specimens. Pontisso et al.
(1987), in a similar study of 50 HBsAg seronegative subjects,
reported that of 42 patients with chronic liver disease, two
Table II Liver HBV-DNA in relation to diagnosis and seropositivity for any marker
Serological results Liver HBV-DNA results
Aetiology HBeAg Anti-HBe Anti-HBs/anti-HBc Free Both Integrated
CAH (66) 13 - 6 1
CAH _ 19 - 5
CAH - - 13 -
Alc. (26) - 1 - -
Alc. - - 3 -
Others (46) - _ 4
HCC (18) 2 - _ 1 1 _
HCC - 5 - - 3 1
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had HBV-DNA in the liver and one of these showed markers
of past infection. Among their eight patients with HCC, one
had HBV-DNA in the presence of anti-HBs and anti-HBc,
but had been HBsAg positive 4 years previously (Giacchino
et al., 1987). Similarly Harrison et al. (1986), in a large series
involving 160 patients, concluded that there was no evidence
to implicate HBV in the pathogenesis of HCC in the absence
of HBV seropositivity.
It is possible that the DNA sample from patient C con-
tained dimeric HBV-DNA without an EcoRl site, in which
case the HBV-DNA would have migrated to the same posi-
tion in each lane; we have noted the same phenomenon
previously (Fagan et al., 1986). This would not have been
expected if the HBV-DNA were integrated. Certainly the
specificity of these bands was confirmed by probing with
vector, and the activities of EcoRl and Hind III by observa-
tion of ethidium bromide stained DNA digests.
Other investigators (Hino et al., 1985; Fowler et al., 1986;
Pasquinelli et al., 1986) have been unable to detect hepatic
HBV-DNA in the absence of serum markers or HBV-RNA
transcripts (Yokosuka et al., 1986). A similar situation occur-
red when using immuno-histochemistry (Blum et al., 1984;
Tur-Kaspa et al., 1986) and in situ hybridisation in combina-
tion with molecular hybridisation (Blum et al., 1983). Liver
HBV-DNA sequences have been detected in patients with
putative NANB hepatitis (Figus et al., 1984), but we, like
Harrison et al. (1986), were unable to confirm these findings
in any of our nine presumed NANB patients.
We cannot be certain why in six of our HBsAg/HBeAg,
with presumed replicating virus, we could detect no hepatic
HBV-DNA sequences. However, two patients were positive
for 6 virus infection, which has been shown to suppress HBV
viral replication, either as a concurrent or as a superimposed
infection (Rizetto et al., 1984); one of two patients treated
with interferon, which has been reported as a successful
antiviral agent (Dusheiko et al., 1986; Alexander et al., 1987),
cleared HBeAg from the serum within one year. Two other
patients were serum DNA polymerase negative, and thus
might have been clearing the virus spontaneously. Another
explanation may be the unequal distribution ofcellular HBV
throughout the liver (Ogata et al., 1988), as well as the
possibility of biopsy sampling error. However, if this occur-
red it was consistent throughout, as the percentages of liver
HBV-DNA in the different populations/high risk groups
closely parallels the frequency of HBsAg seropositivity.
The intimate epidemiological association between HBV
infection and HCC development (Nordenfeldt et al., 1982),
and the high incidence of HCC in HBV related cirrhosis
(Arthur et al., 1984) have led to suggestions that HBV
represents an oncogenic agent in the human liver. Against
this, is the observation that non-hepatic tissues and cells
which contain the HBV genome, albeit in fewer numbers do
not seem prone to malignant transformation (Lie-Injo et al.,
1983; Davison et al., 1987). It has been suggested (Gu, 1988)
that the integration of HBV-DNA into the host
chromosomes corresponds to an initiation event similar to
that found in experimental carcinogenesis when using
aflatoxin Bi or diethylnitrosamine. This on its own need not
cause transformation, but any continuous stimulation of cell
proliferation and its subsequent cell division might cause
integrated HBV-DNA to become susceptible to a disarrange-
ment of molecular sequences, causing clonal expansion and
initiating malignant transformation (Berman, 1988).
From our results, it appears that in order to elucidate the
mechanism of HBV and its action at molecular level,
emphasis must be placed on the investigation of those sub-
jects in whom serum markers of HBV infection can be
demonstrated. It is clear from this and other recent studies
that there is currently little evidence to implicate HBV in the
pathogenesis of HCC in the absence of serum markers,
although this situation may change when more sensitive tech-
niques such as the polymerase chain reaction (PCR) are
applied.
We are indebted to the Cancer Research Campaign for their continu-
ing support.
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